Bausch Health Secures Letter of Intent for Schizophrenia Drug Coverage in Canada — Bausch Health Companies Inc.

Event summary

Bausch Health's PrOKEDI® (Risperidone extended-release injectable suspension) secured a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for public drug plan coverage in Canada.
The LOI covers PrOKEDI® 75mg and 100mg for treating schizophrenia in adults.
PrOKEDI® is designed for rapid plasma concentration attainment and sustained release over a 4-week dosing interval.
The LOI marks a key milestone toward securing public coverage and enabling patient access across Canada.

The big picture

Bausch Health's LOI with the pan-Canadian Pharmaceutical Alliance represents a strategic step toward expanding access to PrOKEDI®, a long-acting injectable antipsychotic for schizophrenia. This move aligns with broader industry trends toward improving patient outcomes through sustained symptom control and reducing relapse risks. The deal underscores the growing importance of long-acting injectables in the neuropsychiatry sector, particularly for chronic conditions like schizophrenia.

What we're watching

Regulatory Approval: Whether Bausch Health can finalize Product Listing Agreements and secure timely public coverage for PrOKEDI®.
Market Penetration: The pace at which PrOKEDI® gains adoption among Canadian patients and healthcare providers.
Competitive Dynamics: How PrOKEDI®'s long-acting injectable formulation will compete with existing antipsychotic treatments in the Canadian market.